All News

Opioids were involved in over two-thirds of overdose deaths in 2017.

Many residency positions draw hundreds of applicants for a single opening.

Cigna recently announced the completion of its $54-billion purchase of Express Scripts.

Newsworthy moments, groundbreaking research, and a continuation of industry trends highlight the most read articles on Specialty Pharmacy Times® of 2018.

From clinical trials evaluating treatments to studies unearthing new discoveries about the disease's mechanism, these were some of the top newsworthy moments in multiple sclerosis research in 2018.

The FDA has approved tagraxofusp-erzs (Elzonris, Stemline Therapeutics) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, aged 2 years and older.

The FDA has approved tagraxofusp-erzs (Elzonris, Stemline Therapeutics) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients, aged 2 years and older.

Ravulizumab (Ultomiris, Alexion) is the first long-acting complement inhibitor approved for the treatment of paroxysmal nocturnal hemoglobinura.

Ravulizumab (Ultomiris, Alexion) is the first long-acting complement inhibitor approved for the treatment of paroxysmal nocturnal hemoglobinura.

Cigna recently announced the completion of its $54-billion acquisition of Express Scripts.

Cigna recently announced the completion of its $54-billion purchase of Express Scripts.

Top news of the week from Specialty Pharmacy Times.

The FDA has approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients, aged 1 month to 21 years.

Top news of the day across the health care landscape.

The FDA has approved calaspargase pegol-mknl (Asparlas, Servier Pharmaceuticals) as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients

The National Hispanic Pharmacists Association was launched by the National Hispanic Health Foundation with public and private sector partners.

Biosimilars present a cost-saving opportunity for the health care system, but significant challenges inhibit uptake in the US market.

Officials with the FDA have approved olaparib (Lynparza, AstraZeneca and MSD) for the maintenance treatment of adult patients with BRCA-mutated advanced ovarian cancer.

Top news of the day across the health care landscape.

Review highlights global patterns in excess body weight, drivers of the epidemic, and contribution to cancer burden.

With this approval, olaparib (Lynparza, AstraZeneca and MSD) is the first approved poly ADP ribose polymerase inhibitor for ovarian cancer.